2026-10602

AI-Enabled Optimization of Early-Phase Clinical Trials Pilot Program; Request for Information; Extension of Comment Period (HHS — Notice)
United States · HHS 2026-10602

Status
Proposed / pending
Applies to
See Federal Register notice — auto-imported, specifics pending verification.
Enforced by
HHS

The Food and Drug Administration (FDA or the Agency) is extending the comment period for the notice entitled "AI-Enabled Optimization of Early-Phase Clinical Trials Pilot Program; Request for Information" that appeared in the Federal Register of April 29, 2026. In the notice, FDA requested comments to solicit input on a proposed pilot program to assess how artificial intelligence (AI)-enabled technologies can improve efficiency, speed, and quality of decision- making in early phase clinical trials. The Agency is taking this action in response to a request for an extension to allow interested p

Who is protected: See Federal Register notice — auto-imported, specifics pending verification.

Legal detail

The Food and Drug Administration (FDA or the Agency) is extending the comment period for the notice entitled "AI-Enabled Optimization of Early-Phase Clinical Trials Pilot Program; Request for Information" that appeared in the Federal Register of April 29, 2026. In the notice, FDA requested comments to solicit input on a proposed pilot program to assess how artificial intelligence (AI)-enabled technologies can improve efficiency, speed, and quality of decision- making in early phase clinical trials. The Agency is taking this action in response to a request for an extension to allow interested persons additional time to submit comments.

Key facts

JurisdictionUnited States
LevelFederal
EnactedMay 28, 2026
CitationHHS 2026-10602
Topicsautomated decision-making
Agency pageFederal Register — HHS — 2026-10602

More AI rules in United States

Related automated decision-making rules elsewhere

See something wrong or out of date? Submit a correction. Every entry must carry a verifiable source.